Haemonetics Corp
Most Recent
Analysts’ Recommendations for Haemonetics and Peers in March 2018
In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.
Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates
Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.
What Analysts Expect from Haemonetics in Q1 2019
Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.
Commercial Launch of NexSys PCS May Boost Haemonetics’s Revenues
Haemonetics is also involved in plasma donor center experience programs that involve the use of NexSys PCS device and YES technology.
The Hospital Business Remains 1of HAE’s Key Growth Drivers
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%.
